相似文献
1
Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy.
Mol Ther. 2010 Apr;18(4):692-9. doi: 10.1038/mt.2009.318. Epub 2010 Jan 19.
2
Combination of viral oncolysis and tumor-specific immunity to control established tumors.
Clin Cancer Res. 2009 Jul 15;15(14):4581-8. doi: 10.1158/1078-0432.CCR-08-2685. Epub 2009 Jul 7.
3
Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
EBioMedicine. 2021 Feb;64:103240. doi: 10.1016/j.ebiom.2021.103240. Epub 2021 Feb 10.
4
IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
J Ovarian Res. 2016 Oct 27;9(1):70. doi: 10.1186/s13048-016-0282-3.
5
Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Theranostics. 2021 May 3;11(14):6668-6681. doi: 10.7150/thno.56494. eCollection 2021.
6
Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
Cancer Res. 2018 Dec 1;78(23):6643-6654. doi: 10.1158/0008-5472.CAN-18-0933. Epub 2018 Oct 8.
7
Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
J Immunother Cancer. 2019 Jul 17;7(1):189. doi: 10.1186/s40425-019-0641-x.
8
Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Hum Gene Ther. 2005 Mar;16(3):348-60. doi: 10.1089/hum.2005.16.348.
9
Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.
Mol Cancer Ther. 2021 Aug;20(8):1481-1494. doi: 10.1158/1535-7163.MCT-20-0863. Epub 2021 May 27.
10
Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA.
J Neurosurg. 2002 Nov;97(5):1184-90. doi: 10.3171/jns.2002.97.5.1184.
引用本文的文献
1
Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed.
Front Immunol. 2022 Oct 6;13:1034903. doi: 10.3389/fimmu.2022.1034903. eCollection 2022.
2
Alphaviruses in Immunotherapy and Anticancer Therapy.
Biomedicines. 2022 Sep 13;10(9):2263. doi: 10.3390/biomedicines10092263.
3
Alphaviruses in Cancer Therapy.
Front Mol Biosci. 2022 Apr 14;9:864781. doi: 10.3389/fmolb.2022.864781. eCollection 2022.
4
Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment.
Mol Ther Oncolytics. 2021 Nov 11;23:488-500. doi: 10.1016/j.omto.2021.11.008. eCollection 2021 Dec 17.
5
Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer.
Vaccines (Basel). 2021 Oct 15;9(10):1187. doi: 10.3390/vaccines9101187.
6
A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity.
Nat Commun. 2021 Aug 31;12(1):5195. doi: 10.1038/s41467-021-25506-6.
7
Delivery of cancer therapies by synthetic and bio-inspired nanovectors.
Mol Cancer. 2021 Mar 24;20(1):55. doi: 10.1186/s12943-021-01346-2.
8
Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19.
Viruses. 2020 Nov 18;12(11):1324. doi: 10.3390/v12111324.
9
Self-Amplifying RNA Viruses as RNA Vaccines.
Int J Mol Sci. 2020 Jul 20;21(14):5130. doi: 10.3390/ijms21145130.
10
Orf Virus-Based Therapeutic Vaccine for Treatment of Papillomavirus-Induced Tumors.
J Virol. 2020 Jul 16;94(15). doi: 10.1128/JVI.00398-20.
本文引用的文献
1
Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.
Mol Ther. 2009 Aug;17(8):1365-72. doi: 10.1038/mt.2009.118. Epub 2009 May 26.
2
Measles virus for cancer therapy.
Curr Top Microbiol Immunol. 2009;330:213-41. doi: 10.1007/978-3-540-70617-5_11.
3
Oncolytic viruses: a novel form of immunotherapy.
Expert Rev Anticancer Ther. 2008 Oct;8(10):1581-8. doi: 10.1586/14737140.8.10.1581.
4
Immunotherapeutic potential of oncolytic virotherapy.
Lancet Oncol. 2008 Jul;9(7):610-2. doi: 10.1016/S1470-2045(08)70163-3.
5
Enhancing poxvirus oncolytic effects through increased spread and immune evasion.
Cancer Res. 2008 Apr 1;68(7):2071-5. doi: 10.1158/0008-5472.CAN-07-6515.
6
Poxvirus cancer therapy.
Recent Pat Antiinfect Drug Discov. 2006 Nov;1(3):309-21. doi: 10.2174/157489106778777592.
7
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.
Cancer Res. 2007 Feb 1;67(3):1326-34. doi: 10.1158/0008-5472.CAN-06-3290.
8
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice.
Gene Ther. 2007 Jan;14(1):20-9. doi: 10.1038/sj.gt.3302840. Epub 2006 Aug 17.
9
In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.
J Clin Invest. 2006 Jul;116(7):1946-54. doi: 10.1172/JCI28045. Epub 2006 Jun 22.
10
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.
Cancer Res. 2006 Jun 1;66(11):5910-8. doi: 10.1158/0008-5472.CAN-05-3905.
Zotero 插件